Factors Contributing to Negative Outcomes Associated with Medications and Drug-Related Problems in Kidney Replacement Therapy—A Hospital-Based Prospective Observational Study
-
Published:2024-02-12
Issue:4
Volume:13
Page:1048
-
ISSN:2077-0383
-
Container-title:Journal of Clinical Medicine
-
language:en
-
Short-container-title:JCM
Author:
Pereira-Céspedes Alfonso1234ORCID, Jiménez-Morales Alberto12, Polo-Moyano Aurora4, Palomares-Bayo Magdalena4, Martínez-Martínez Fernando1, Calleja-Hernández Miguel Ángel15
Affiliation:
1. Pharmaceutical Care Research Group, Pharmacy Faculty, University of Granada, 18071 Granada, Spain 2. Pharmacy Department, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain 3. Centro Nacional de Información de Medicamentos, Instituto de Investigaciones Farmacéuticas, Pharmacy Faculty, University of Costa Rica, San José 11501-2060, Costa Rica 4. Nephrology Department, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain 5. Pharmacy Department, Hospital Universitario Virgen Macarena, 41009 Seville, Spain
Abstract
Background: Negative outcomes associated with medications (NOM) and drug-related problems (DRP) significantly impact individuals with kidney replacement therapy (KRT) given the complexities of managing kidney disease and associated comorbidities. The present study aims to assess the frequency of NOMs/DRPs among KRT patients and identify contributing factors. Methods: A cross-sectional study was conducted at Virgen de las Nieves University Hospital (Granada, Spain), involving 117 outpatient adults with KRT. Data were collected from February 2021 to July 2023 using electronic records, semi-structured interviews (Dáder Method), and discussions with nephrology specialists. NOMs/DRPs were identified following treatment guidelines. Binary logistic regression was used to determine associated factors (p-value < 0.05). Results: Across 117 patients, 2436 NOMs and 3303 DRPs were identified, averaging 20.82 NOMs and 28.23 DRPs per patient. Prevalent NOMs included untreated conditions (58.95%), quantitative ineffectiveness (35.43%), and non-quantitative safety problems (5.13%). Dominant DRPs were undertreated conditions (37.63%), wrong dose/posology/length (33.00%), risk of adverse drug reactions (ADR) (16.14%), and non-adherence (6.87%). Patients with ADR, undertreated conditions, and anemia were associated with quantitative ineffectiveness. Risk of ADR and vitamin D deficiency/insufficiency correlated with non-quantitative safety problems. Conclusions: KRT patients exhibited a substantial prevalence of NOMs/DRPs. Further research is needed to deepen our understanding of these complexities for improved patient care.
Funder
Office of International Affairs and External Cooperation, University of Costa Rica Fundación para la Investigación Biosantitaria de Andalucía Oriental-Alejandro Otero
Reference18 articles.
1. Pereira-Céspedes, A., Jiménez-Morales, A., Palomares-Bayo, M., Martínez-Martínez, F., and Calleja-Hernández, M. (2023). Medication review with follow-up for end-stage renal disease: Drug-related problems and negative outcomes associated with medication—A systematic review. J. Clin. Med., 12. 2. Pharmacists’ strategies to detect, resolve, and prevent DRPs in CKD patients;Susilawati;Pharmacia,2021 3. Kim, A.J., Lee, H., Shin, E.-J., Cho, E.-J., Cho, Y.S., Lee, H., and Lee, J.-Y. (2021). Pharmacist-led collaborative medication management for the elderly with chronic kidney disease and polypharmacy. Int. J. Environ. Res. Public Health, 18. 4. Legesse, E.S., Muhammed, O.S., Hamza, L., Nasir, B.B., and Nedi, T. (2022). Medication related problems among ambulatory patients with chronic kidney disease at St. Paul’s Hospital Millennium Medical College, Addis Ababa, Ethiopia. PLoS ONE, 17, Available online: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0278563. 5. Alshamrani, M., Almalki, A., Qureshi, M., Yusuf, O., and Ismail, S. (2018). Polypharmacy and medication-related problems in hemodialysis patients: A call for deprescribing. Pharmacy, 6.
|
|